Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Briganti

Showing results (31-40 of 1,747) with videos related to

Pageof 175
Sort By:
European Urology|October 2, 2021
Re: Andrew J. Vickers. Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer. Eur Urol 2021;80:567-72Francesco Montorsi, Giorgio Gandaglia, Alberto Briganti
The Lancet. Oncology|October 22, 2021
Reimagining prostate cancer screening: the IMPACT of germline mutationsGiorgio Gandaglia, Alberto Briganti, Francesco Montorsi
The Journal of Urology|October 25, 2019
Re: Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter TrialFrancesco Montorsi, Marco Moschini, Alberto Briganti
European Urology|April 12, 2008
Editorial comment on: preliminary results of a novel method to estimate the probability of prostate cancer in men with elevated serum PSA valuesFelix K-H Chun, Alberto Briganti
The Journal of Urology|April 22, 2025
Letter: A Multi-Institutional Study of Magnetic Resonance/Ultrasound Fusion-Guided Nanoparticle-Directed Focal Therapy for Prostate AblationFrancesco Montorsi, Armando Stabile, Alberto Briganti
European Urology|October 16, 2018
Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 2018;74:294-306: Validating VI-RADS Criteria Within Immune-oncology Strategies (VI-RADS-IO)Andrea Necchi, Antonella Messina, Alberto Briganti
The Lancet. Oncology|December 17, 2008
The importance of the extent of pelvic-lymph-node dissection in the diagnosis of lymph-node metastases in prostate cancerAlberto Briganti, Patrizio Rigatti, Francesco Montorsi
JAMA|August 21, 2014
Tadalafil for erectile dysfunction prevention after radiotherapy for prostate cancerFabio Castiglione, Francesco Montorsi, Alberto Briganti
BJU International|November 11, 2014
Long-term outcomes of robot-assisted radical prostatectomy: Where do we stand?Francesco Montorsi, Giorgio Gandaglia, Alberto Briganti
European Urology|December 4, 2014
Re:Mark K. Buyyounouski. Radiobiological modeling and the study of hypofractionated radiotherapy for prostate cancer. Eur Urol 2014;66:1031-2Claudio Fiorino, Alberto Briganti, Cesare Cozzarini
Pageof 175

Showing results (31-40 of 1,747) with videos related to

Sort By:
Pageof 175
European Urology|October 2, 2021
Re: Andrew J. Vickers. Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer. Eur Urol 2021;80:567-72Francesco Montorsi, Giorgio Gandaglia, Alberto Briganti
The Lancet. Oncology|October 22, 2021
Reimagining prostate cancer screening: the IMPACT of germline mutationsGiorgio Gandaglia, Alberto Briganti, Francesco Montorsi
The Journal of Urology|October 25, 2019
Re: Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter TrialFrancesco Montorsi, Marco Moschini, Alberto Briganti
European Urology|April 12, 2008
Editorial comment on: preliminary results of a novel method to estimate the probability of prostate cancer in men with elevated serum PSA valuesFelix K-H Chun, Alberto Briganti
The Journal of Urology|April 22, 2025
Letter: A Multi-Institutional Study of Magnetic Resonance/Ultrasound Fusion-Guided Nanoparticle-Directed Focal Therapy for Prostate AblationFrancesco Montorsi, Armando Stabile, Alberto Briganti
European Urology|October 16, 2018
Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 2018;74:294-306: Validating VI-RADS Criteria Within Immune-oncology Strategies (VI-RADS-IO)Andrea Necchi, Antonella Messina, Alberto Briganti
The Lancet. Oncology|December 17, 2008
The importance of the extent of pelvic-lymph-node dissection in the diagnosis of lymph-node metastases in prostate cancerAlberto Briganti, Patrizio Rigatti, Francesco Montorsi
JAMA|August 21, 2014
Tadalafil for erectile dysfunction prevention after radiotherapy for prostate cancerFabio Castiglione, Francesco Montorsi, Alberto Briganti
BJU International|November 11, 2014
Long-term outcomes of robot-assisted radical prostatectomy: Where do we stand?Francesco Montorsi, Giorgio Gandaglia, Alberto Briganti
European Urology|December 4, 2014
Re:Mark K. Buyyounouski. Radiobiological modeling and the study of hypofractionated radiotherapy for prostate cancer. Eur Urol 2014;66:1031-2Claudio Fiorino, Alberto Briganti, Cesare Cozzarini
Pageof 175